Biblio
Export 1530 results:
Author [ Title
Filters: First Letter Of Last Name is K [Clear All Filters]
“Change of Amyloid-β 1-42 Toxic Conformer Ratio After Cerebrospinal Fluid Diversion Predicts Long-Term Cognitive Outcome in Patients with Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 63, no. 3, pp. 989-1002, 2018.
, “Challenges and Considerations Related to Studying Dementia in Blacks/African Americans.”, J Alzheimers Dis, vol. 60, no. 1, pp. 1-10, 2017.
, “CFH and ARMS2 Polymorphisms Interact with Zinc Supplements in Cognitive Impairment in the Women's Health Initiative Hormone Trial.”, J Alzheimers Dis, vol. 66, no. 2, pp. 707-715, 2018.
, “Cerebrospinal Fluid Sulfatide Levels Lack Diagnostic Utility in the Subcortical Small Vessel Type of Dementia.”, J Alzheimers Dis, vol. 82, no. 2, pp. 781-790, 2021.
, “Cerebrospinal Fluid sTREM-2, GFAP, and β-S100 in Symptomatic Sporadic Alzheimer's Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimer's Disease Continuum.”, J Alzheimers Dis, vol. 92, no. 4, pp. 1385-1397, 2023.
, “Cerebrospinal Fluid Sphingomyelins in Alzheimer's Disease, Neurodegeneration, and Neuroinflammation.”, J Alzheimers Dis, vol. 90, no. 2, pp. 667-680, 2022.
, “Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 467-475, 2023.
, “Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 467-475, 2023.
, “Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 467-475, 2023.
, “The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.”, J Alzheimers Dis, vol. 53, no. 4, pp. 1523-38, 2016.
, “Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study.”, J Alzheimers Dis, vol. 59, no. 4, pp. 1327-1334, 2017.
, “Cerebrospinal Fluid Metals and the Association with Cerebral Small Vessel Disease.”, J Alzheimers Dis, vol. 78, no. 3, pp. 1229-1236, 2020.
, “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
, “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
, “Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 581-588, 2018.
, “Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.”, J Alzheimers Dis, vol. 55, no. 1, pp. 19-35, 2017.
, “Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia.”, J Alzheimers Dis, vol. 55, no. 4, pp. 1453-1461, 2017.
, “Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia.”, J Alzheimers Dis, vol. 55, no. 4, pp. 1453-1461, 2017.
, “Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia.”, J Alzheimers Dis, vol. 55, no. 4, pp. 1453-1461, 2017.
, “Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 58, no. 3, pp. 939-950, 2017.
, “Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 58, no. 3, pp. 939-950, 2017.
, “Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 58, no. 3, pp. 939-950, 2017.
, “Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting.”, J Alzheimers Dis, vol. 57, no. 2, pp. 437-445, 2017.
, “Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 2, pp. 813-822, 2017.
, “Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage.”, J Alzheimers Dis, vol. 62, no. 1, pp. 385-397, 2018.
,